PROSPECTUS | Filed
Pursuant to Rule 424(b)(3) |
| Registration
No. 333-268144 |
Bioceres Crop Solutions Corp.
(incorporated in the Cayman Islands)
This prospectus relates to
the resale, from time to time, of (i) 4,755,684 ordinary shares, par value $0.0001 per share (“ordinary shares”) of Bioceres
Crop Solutions Corp., (ii) 14,759 ordinary shares previously registered pursuant to our registration on Form F-1 (File No. 333-231883),
which we filed with the SEC on May 31, 2019, and was declared effective by the SEC on July 15, 2019 (the “F-1 Registration
Statement”), (iii) 122,883 ordinary shares previously registered pursuant to our registration on Form F-3 (File No. 333-237496),
which we filed with the SEC on March 31, 2020 and was declared effective by the SEC on April 16, 2020 (the “March 2020
F-3 Registration Statement”), and (iv) 37,917 ordinary shares previously registered pursuant to our registration statement
on Form F-3 (File No. 333-249770), which we filed with the SEC on October 30, 2020 relating to the Secured Convertible
Guaranteed Notes due 2023 and which was declared effective by the SEC on November 6, 2020 (the “October 2020 F-3 Registration
Statement”, together with the F-1 Registration Statement and the March 2020 F-3 Registration Statement, the “Prior Registration
Statements”). Pursuant to Rule 429 under the Securities Act of 1933, as amended (the “Securities Act”), this prospectus
updates the prior registration statements and includes ordinary shares previously registered by us pursuant to such prior registration
statements.
The ordinary shares are being
offered by the selling shareholders identified herein and we will not receive any proceeds from the sale of the securities under this
prospectus. Information regarding the selling shareholders, the number of ordinary shares that may be sold by them, and the times and
manner in which they may offer and sell the ordinary shares under this prospectus is provided under the sections titled “Selling
Shareholders” and “Plan of Distribution,” respectively. We do not know when or in what amount the selling shareholders
may offer the securities for sale. The selling shareholders may sell any, all, or none of the securities offered by this prospectus.
Our ordinary shares trade
on the Nasdaq Global Market (“Nasdaq”) under the symbol “BIOX”. The last sale price of our ordinary shares on
November 17, 2022 was US$13.36 per share.
Investing
in our securities involves risks. See “Risk Factors” beginning on page 6 to read about factors you should consider before
buying our securities.
Neither
the Securities and Exchange Commission nor any state or foreign securities commission has approved or disapproved of these securities
or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
Prospectus dated November 18, 2022.
TABLE OF CONTENTS
About
This Prospectus
This prospectus is part of
a registration statement that we filed with the SEC utilizing a shelf registration process. Under this shelf process, any of the securities
identified in this prospectus may be offered together or separately in one or more series, if any. The selling shareholders may offer
and sell any combination of the securities identified in this prospectus.
This prospectus provides
you with a general description of the securities the selling shareholders may offer. Each time the selling shareholders sell securities,
we will provide a prospectus supplement that will contain specific information about the terms of those securities and their offering,
including the specific amounts, prices and terms of the offered securities. The prospectus supplement may also add, update or change information
contained in this prospectus. You should read both this prospectus and any prospectus supplement together with the additional information
described under the headings “Risk Factors,” “Where You Can Find More Information” and “Incorporation of
Documents by Reference.”
This prospectus and any accompanying
prospectus supplement do not contain all of the information included in the registration statement as permitted by the rules and
regulations of the SEC. For further information, we refer you to the registration statement on Form F-3, including its exhibits.
If you are in a jurisdiction where offers to sell, or solicitations of offers to purchase, the securities offered by this document are
unlawful, or if you are a person to whom it is unlawful to direct these types of activities, then the offer presented in this document
does not extend to you.
You should assume that the
information in this prospectus or any prospectus supplement, as well as the information incorporated by reference in this prospectus or
any prospectus supplement, is accurate only as of the date of the documents containing the information, unless the information specifically
indicates that another date applies. Our business, financial condition, results of operations and prospects may have changed since those
dates.
Wherever references are made
in this prospectus to information that will be included in a prospectus supplement, to the extent permitted by applicable law, rules or
regulations, we may instead include such information or add, update or change the information contained in this prospectus by means of
a post-effective amendment to the registration statement of which this prospectus is a part, through filings we make with the SEC that
are incorporated by reference in this prospectus or by any other method as may then be permitted under applicable law, rules or regulations.
Unless otherwise indicated
or the context otherwise requires, all references in this prospectus to “BIOX” or the “Company,” “we,”
“our,” “ours,” “us” or similar terms refer to Bioceres Crop Solutions Corp., together with its subsidiaries.
The ordinary shares that may be offered using this prospectus are referred to collectively as the securities.
Incorporation
of Certain Information by Reference
This prospectus
incorporates important business and financial information about that is not included in or delivered with the prospectus. The SEC
allows BIOX to “incorporate by reference” information filed with the SEC, which means that we can disclose important
information to you by referring you to those documents. The information incorporated by reference is considered to be part of this
prospectus, and certain later information that BIOX files with the SEC will automatically update and supersede this information.
This document incorporates
by reference the following documents that have previously been filed with the SEC by BIOX:
| · | The Amended and Restated Memorandum and Articles of Association of Bioceres Crop Solutions Corp. (filed
with the SEC as Exhibit 3.1 to Amendment No.1 to BIOX’s registration statement on Form F-1 (File No. 333-231883),
filed with the SEC on July 12, 2019). |
This
document incorporates by reference the following documents that have previously been filed with the SEC by Pro Farm Group, Inc.
(formerly Marrone Bio Innovations, Inc.) (“Pro Farm”):
In addition, BIOX is
incorporating by reference any documents it may file under Section 13(a), 13(c), 14 or 15(d) of the Exchange Act on or
after the date of the registration statement on Form F-3 filed by BIOX on November 11, 2022, and prior to the effectiveness of this
registration statement of which this prospectus forms a part, provided, however, that BIOX is not incorporating by reference any information furnished (but not filed),
except as otherwise specified herein.
Information that we file
with the SEC will automatically update and supersede the information included in this prospectus or previously incorporated by reference
into this prospectus. All information appearing in this prospectus is qualified in its entirety by the information and financial statements,
including the notes, contained in the documents that we incorporate by reference in this prospectus.
We will provide to each person,
including any beneficial owner, to whom a prospectus is delivered, a copy of any or all of the information that has been incorporated
by reference in the prospectus but not delivered with the prospectus.
You may request a copy of
these filings, at no cost, by writing or telephoning us at the following address:
Bioceres Crop Solutions Corp.
Ocampo 210 bis
Predio CCT, Rosario, Santa Fe, Argentina
Tel: +54 (341) 486-1122
investorrelations@biocerescrops.com
You
should rely only on the information that we incorporate by reference or provide in this prospectus or the accompanying prospectus supplement.
We have not authorized anyone to provide you with different information. You should not assume that the information in this prospectus
or any prospectus supplement is accurate as of any date other than the date on the front of those documents. Documents incorporated
by reference are available on the SEC’s website at www.sec.gov and from other sources. You may read and copy any materials filed
with the SEC at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. You may obtain information on the
operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. Additionally, the SEC maintains an Internet site that contains
reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC (http://www.sec.gov).
Summary
This summary highlights
selected information appearing elsewhere or incorporated by reference herein; it does not contain all of the information that is important
to you. You should read this prospectus, including the information incorporated by reference, in its entirety. Investors should carefully
consider the information set forth under the “Risk Factors” section.
Overview
We are a fully integrated
provider of crop productivity technologies designed to enable the transition of agriculture towards carbon neutrality. To achieve this,
we create economic incentives for growers and other stakeholders to adopt environmentally friendly production practices. We have a unique
biotech platform with high-impact, licensed and patented technologies for seeds and microbial ag-inputs, as well as biological and next
generation conventional crop nutrition and protection solutions. Along with our licensed HB4 – drought tolerant seed technology
program, we also bring digital solutions to support growers’ decisions and provide end-to-end traceability for production outputs.
We are a global company, as our agricultural inputs are marketed across more than 40 countries, primarily in South America and the United
States. We are well positioned with geographic exposure to the global soybean and wheat production footprint.
Our leading infrastructure,
the success of our unique biotech platform, and a commanding presence in our key markets have made us a flagship agricultural solutions
provider, as well as the natural partner for global conglomerates.
For additional information,
see our most recent annual report for the fiscal year ended June 30, 2022 on Form 20-F, filed with the SEC on October 28, 2022 (the “Annual Report”).
Corporate Information
Our principal executive offices
are located at Ocampo 210 bis, Predio CCT, Rosario, Santa Fe, Argentina, and our telephone number is +54 341 486-1100. We were incorporated
as an exempted company under the laws of the Cayman Islands. Our agent for service of process in the United States is Cogency Global Inc.,
122 East 42nd Street, 18th Floor, New York, NY 10168.
Risk
Factors
Investing in the securities
offered using this prospectus involves risk. Before you decide to buy our securities, you should carefully consider the risks described
under the heading “Risk Factors” in our Annual Report, which is incorporated herein by reference, in the applicable prospectus
supplement and in other documents incorporated by reference into this prospectus. If any of these risks actually occur, our business,
financial condition and results of operations could suffer, and the trading price and liquidity of the securities offered using this prospectus
could decline, in which case you may lose all or part of your investment. Please see “Where You Can Find More Information”
and “Incorporation of Documents by Reference” for information on where you can find the documents we have filed with or furnished
to the SEC and which are incorporated into this prospectus by reference.
Special
Note Regarding Forward-Looking Statements
We make forward-looking statements
in this prospectus that are subject to risks and uncertainties. These forward-looking statements include information about possible or
assumed future results of our business, financial condition, results of operations, liquidity, anticipated growth strategies, anticipated
trends in our industry, our potential growth opportunities, plans and objectives. In some cases, you can identify forward-looking statements
by terminology such as “believe,” “may,” “might,” “will,” “consider,” “estimate,”
“continue,” “anticipate,” “intend,” “target,” “project,” “contemplate,”
“should,” “plan,” “expect,” “predict,” “potential,” or the negative of these
terms or other similar terms or expressions. The statements we make regarding the following matters are forward-looking by their nature:
| · | the impact of the conflict between Russia and Ukraine on our business; |
| · | our ability to develop and commercialize biotechnology products and crop productivity technologies; |
| · | our ability to maintain our joint venture agreements with our current partners; |
| · | the success of the HB4 technology that we license and that remains subject to receipt of regulatory approval
in certain jurisdictions other than Argentina; |
| · | our or our collaborators’ ability to develop commercial products that incorporate our licensed seed
traits and complete the regulatory approval process for such products; |
| · | our expectations regarding the commercial value of our key products in yield and abiotic stress and biotic
stress; |
| · | our expectations regarding regulatory approval of products developed or licensed by us, our joint ventures
and third-party collaborators; |
| · | our ability to adapt to continuous technological change in our industry; |
| · | our expectations that products containing our licensed seed traits will be commercialized and we will
earn royalties from the sales of such products; |
| · | our expectations to accelerate the Microstar ramp up, our leading brand in micro-granulated fertilizers; |
| · | our expectations regarding the future growth of the global agricultural, agricultural biotechnology, biological-based
chemical and agro-industrial biotechnology markets; |
| · | our ability to develop and exploit a proprietary channel for the sale of our licensed biotechnology products; |
| · | our compliance with laws and regulations that impact our business and changes to such laws and regulations; |
| · | our ability to assemble, store, integrate and analyze significant amounts of public and proprietary data; |
| · | our ability to respond to health epidemics and other outbreaks, such as COVID-19, including responses
by governmental bodies or regulators; |
| · | our ability to maintain our licensing arrangements for the products that we commercialize; |
| · | the impact of COVID-19 on the economy, our customers, employees and vendors as well as on our business,
financial condition and results of operations; |
| · | the outcome of any known and unknown litigation and regulatory proceedings; and |
| · | various other factors, including without limitation those described under “Risk Factors.” |
The preceding list is not
intended to be an exhaustive list of all of our forward-looking statements. The forward-looking statements are based on our beliefs, assumptions
and expectations of future performance, taking into account the information currently available to us. These statements are only predictions
based upon our current expectations and projections about future events. There are important factors that could cause our actual results,
levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements
expressed or implied by the forward-looking statements.
You should not rely upon
forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected
in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly
any forward-looking statements for any reason after the date of this prospectus or to conform these statements to actual results or to
changes in our expectations.
Enforcement
of Civil Liberties
Cayman Islands
We are incorporated under
the laws of Cayman Islands. Substantially all of our and our subsidiaries’ assets are located outside the United States. Substantially
all of our directors and officers and certain advisors named in this prospectus reside in Argentina. As a result, it may not be possible
for investors to effect service of process within the United States upon such persons or to enforce against them or us in United States
courts judgments predicated upon the civil liability provisions of the federal securities laws of the United States.
The Cayman Islands has a
different body of securities laws as compared to the United States and provides less protection to investors. Additionally, Cayman Islands
companies may not have standing to sue before the Federal courts of the United States.
We have been advised by our
Cayman Islands legal counsel, Maples and Calder (Cayman) LLP, that the courts of the Cayman Islands are unlikely (i) to recognize
or enforce against us judgments of courts of the United States predicated upon the civil liability provisions of the federal securities
laws of the United States or any state; and (ii) in original actions brought in the Cayman Islands, to impose liabilities against
us predicated upon the civil liability provisions of the federal securities laws of the United States or any state, so far as the liabilities
imposed by those provisions are penal in nature. In those circumstances, although there is no statutory enforcement in the Cayman Islands
of judgments obtained in the United States, the courts of the Cayman Islands will recognize and enforce a foreign money judgment of a
foreign court of competent jurisdiction without retrial on the merits based on the principle that a judgment of a competent foreign court
imposes upon the judgment debtor an obligation to pay the sum for which judgment has been given provided certain conditions are met. For
a foreign judgment to be enforced in the Cayman Islands, such judgment must be final and conclusive and for a liquidated sum, and must
not be in respect of taxes or a fine or penalty, inconsistent with a Cayman Islands judgment in respect of the same matter, impeachable
on the grounds of fraud or obtained in a manner, and or be of a kind the enforcement of which is, contrary to natural justice or the public
policy of the Cayman Islands (awards of punitive or multiple damages may well be held to be contrary to public policy). A Cayman Islands
Court may stay enforcement proceedings if concurrent proceedings are being brought elsewhere.
Argentina
We have been advised by our
Argentine counsel, Marval O’Farrell Mairal, of the uncertainty in terms of extent and timeliness for enforceability of liabilities
predicated solely upon the federal securities laws of the United States in original actions in Argentine courts as compared to actions
brought in a United States or other non-Argentine court, as well as with respect to the enforceability of judgments of United States courts
in Argentine courts that were obtained in actions against us or the persons described above, that were predicated upon the civil liability
provisions of the federal securities laws of the United States and which will be subject to compliance with certain requirements under
Argentine law mentioned below, including the condition that any such judgment does not violate Argentine public policy (orden público).
If enforcement of a judgment
issued by a U.S. court is sought before federal courts or courts with jurisdiction in commercial matters of the City of Buenos Aires,
such judgment will be recognized and enforced by the courts in Argentina, provided that the requirements set out in Articles 517 through
519 of the Argentine Federal Civil and Commercial Procedure Code are met. Such requirements are as follows: (1) the judgment, which
must be valid and final in the jurisdiction where rendered, was issued by a competent court in accordance with the Argentine principles
regarding international jurisdiction and resulted from a personal action, or an in rem action with respect to personal property which
was transferred to Argentine territory during or after the prosecution of the foreign action, (2) the defendant against whom enforcement
of the judgment is sought was personally served with the summons and, in accordance with due process of law, was given an opportunity
to defend against the foreign action, (3) the authenticity of the judgment must be established in accordance with the requirements
of Argentine law, (4) the judgment does not violate the principles of public policy of Argentine law, and (5) the judgment is
not contrary to a prior or simultaneous judgment of an Argentine court. Any document in a language other than Spanish (including, without
limitation, the foreign judgment and other documents related thereto) requires filing with the relevant court of a duly legalized translation
by a sworn public translator into the Spanish language. Any public document issued in any country other than Argentina must be duly legalized
before the competent Argentine Consulate and before the Ministry of Foreign Relations of Argentina, or if such country is part of the
Convention Abolishing the Requirement of Legalization for Foreign Public Documents adopted at The Hague on October 5, 1961, must
bear the “Apostille” provided in such Convention.
Enforcement of foreign judgments
before the provincial courts of the Province of Santa Fe would be recognized provided that the requirements of Articles 269 through 271
of the Procedure Code of the Province of Santa Fe (approved by Law No. 5,531, as amended) are met as follows: (1) the judgment
must not invalidate the jurisdiction of the Argentine courts; (2) if the defendant was domiciled in Argentina, the judgment must
have not been issued as a default judgment; (3) the judgment must be valid according to Argentine law and must not violate the principles
of public policy (public order) in Argentina; (4) the judgment must be valid in the jurisdiction where rendered and its authenticity
must be established in accordance with the requirements of Argentine law; (5) if the jurisdiction where the judgment was rendered
includes any additional requirement to enforce judgments rendered in Argentina, the judgment must also comply with such additional requirements;
and (6) judgments rendered in Argentina must be enforceable in the jurisdiction where the judgment was rendered. Petition for enforcement
shall be accompanied by authenticated copy of the relevant foreign laws evidencing satisfaction of the requirements described above, as
applicable, duly translated by a sworn public translator into the Spanish language. Any public document issued in any country other than
Argentina must be duly legalized before the competent Argentine Consulate and before the Ministry of Foreign Relations of Argentina, or
if such country is part of the Convention Abolishing the Requirement of Legalization for Foreign Public Documents adopted at The Hague
on October 5, 1961, must bear the “Apostille” provided in such Convention.
The filing of claims with
the Argentine judicial system is subject to the payment of a court tax to be paid by the person filing a claim. Such tax rate varies from
one jurisdiction to another (the current court tax in the courts sitting in the City of Buenos Aires is levied at a rate of 3% of the
amount claimed, in conformity with Article 2 of Argentine Law No. 23,898; the current court tax in the courts sitting in the
Province of Santa Fe is also levied, for ordinary proceedings, at a rate of 3% of the amount claimed, in conformity with Articles 35 and
36 of Santa Fe Province Tax Law No. 3,650. Furthermore, pursuant to Argentine Law No. 26,589 (as amended), certain mediation
procedures must be exhausted prior to the initiation of lawsuits in Argentina (with the exception, among others, of bankruptcy and executory
proceedings, which executory proceedings include the enforcement of foreign judgments, in which case mediation procedures remain optional
for the plaintiff). A similar procedure, that is optional for the party trying to enforce a judgment obtained abroad in the Province of
Santa Fe, may be followed as provided by Provincial Law No. 13,151 and its regulatory Decree No. 1747/2011 of the Province of
Santa Fe. Enforcement of claims in Argentina may become limited by statute of limitations or the lapse of time.
Subject to compliance with
Article 517 of the Argentine Federal Civil and Commercial Procedure Code or Article 269 of the Procedure Code of the Province
of Santa Fe, as described above, a judgment against us or the persons described above and obtained outside Argentina would be enforceable
in Argentina without reconsideration of the merits.
Pursuant to Articles 102
through 104 of the Argentine Law No. 27,449, awards issued by foreign arbitral tribunals will be recognized and enforced by the courts
in Argentina except where: (i) at the instance of either party, the court finds that (1) one of the parties to the arbitration
clause was legally incapacitated; (2) the arbitral clause was not valid under the law elected by the parties or otherwise by the
law of the jurisdiction where the award was granted; (3) the party against whom the award is enforced was not served notice of the
appointment of the arbitrators or of the arbitration proceedings or otherwise did not have the opportunity to defend; (4) the award
refers to issues not submitted to arbitration or exceeds the terms of the arbitration clause; (5) the appointment of the arbitral
tribunal or the arbitration procedure did not comply with the arbitration clause or with the laws of the jurisdiction where the arbitration
took place; or (6) the award is not yet enforceable or was suspended or annulled by a court of the jurisdiction where granted; or
(ii) the court finds that: (1) the claim may not be submitted to arbitration under Argentine law; or (2) the recognition
and enforcement of the award would violate the principles of international public policy under Argentine law.
Enforcement of claims and
foreign judgments and submission to arbitration and enforcement of awards in Argentina are limited by bankruptcy, insolvency, reorganization,
out of court restructuring, moratorium or similar laws of general applicability affecting the enforcement of creditors’ rights.
If insolvency proceedings
are commenced in Argentina, the admission of creditors whose claims are payable outside Argentina and which do not belong to a foreign
insolvency proceeding (whether because no such proceedings have been initiated or commenced or otherwise) is conditional upon submission
of evidence that, reciprocally, a creditor whose claim is payable in Argentina may be allowed and paid pari passu in insolvency
proceedings commenced in the country where the claim of the former is payable; provided, however, that if bankruptcy is also declared
outside Argentina, any creditors who made a filing in the foreign bankruptcy proceedings will only be entitled to claim against the balance
of assets remaining in Argentina, once all creditors in the bankruptcy proceedings in Argentina have been paid in full.
We have been further advised
by our Argentine counsel that the ability of a judgment creditor or the other persons named above to satisfy a judgment by attaching certain
assets of ours, or of any of our directors, our executive officers and/or the advisors named in this prospectus, respectively, may be
limited by provisions of Argentine law.
Capitalization
Our capitalization will be
set forth in a prospectus supplement to this prospectus or in a report of foreign private issuer on Form 6-K subsequently furnished
to the SEC and specifically incorporated herein by reference.
Selling
Shareholders
The selling shareholders
may from time to time offer and sell any or all of our securities set forth below pursuant to this prospectus. When we refer to “selling
shareholders” in this prospectus, we mean the persons listed in the table below, and the pledgees, donees, permitted transferees,
assignees, successors, and others who later come to hold any of the selling shareholders’ interests in our securities other than
through a public sale.
We have registered the resale
of (i) 14,759 ordinary shares that remain unsold from the 119,443 ordinary shares registered pursuant to the F-1 Registration Statement,
(ii) 122,883 ordinary shares that remain unsold from the 1,432,571 ordinary shares previously registered pursuant to the March 2020
F-3 Registration Statement, (iii) 37,917 ordinary shares that remain unsold from the 7,469,488 ordinary shares previously registered
pursuant to the October 2020 F-3 Registration Statement relating to the Secured Convertible Guaranteed Notes due 2023 and (iv) 3,582,968
ordinary shares underlying the Secured Convertible Guaranteed Notes due 2026 included in this prospectus, in order to permit such selling
shareholders to offer the ordinary shares for resale from time to time. This prospectus covers the resale of the ordinary shares held
by the selling shareholders and the maximum number of ordinary shares issuable upon conversion of the Secured Convertible Guaranteed Notes
due 2026.
The 14,759 ordinary shares
that remain unsold from the 119,443 ordinary shares registered pursuant to the F-1 Registration Statement were issued to minority shareholders
of Bioceres Semillas S.A.U. upon the exercise of their tag-along rights under a shareholders agreement, in connection with the consummation
of the business combination.
The Secured Convertible Guaranteed
Notes due 2023 were sold in a private placement to Solel-Bioceres SPV, L.P. and Ari Freisinger. We repurchased 1,526,454 ordinary shares
issued pursuant to the Secured Guaranteed Notes due 2026 transaction and hold such ordinary shares in treasury. See our Annual Report
on Form 20-F “Item 4. Information on the Company—Material Contracts—Issuance of Notes due 2026—Secured Guaranteed
Notes due 2026.”
According to information
derived from the registration statement on Form S-4 filed with the SEC by UAC on December 21, 2018, the 122,883 ordinary shares
that remain unsold from the 1,432,571 ordinary shares previously registered pursuant to the March 2020 F-3 Registration Statement
were part of the ordinary shares issued by UAC in December 2017 to Kyle P. Bransfield, UAC’s chief executive officer, and Union
Group International Holdings Limited (“UGI”), an affiliate of Juan Sartori, the Chairman of UAC’s board of directors,
in connection with UAC’s organization, and Mr. Bransfield and UGI subsequently transferred a portion of such shares to certain
individuals and entities, including UAC’s independent directors.
The 3,582,968 ordinary shares
underlying the Secured Convertible Guaranteed Notes due 2026 and included in this prospectus comprise both principal and interest payable
in kind, of which may be converted into ordinary sharers at the option of the holders of the Secured Convertible Guaranteed Notes due
2026. The Secured Convertible Guaranteed Notes due 2026 were sold in a private placement to Jasper Lake Ventures One LLC, Redwood Enhanced
Income Corp. and Liminality Partners LP. See “Description of Share Capital— Secured Guaranteed Notes due 2026” in this
prospectus and “Item 4. Information on the Company—Material Contracts—Issuance of Notes due 2026—Secured Guaranteed
Notes due 2026” in our Annual Report on Form 20-F.
The following table sets
forth, as of the date of this prospectus:
| · | the name of each selling shareholder for whom we are registering ordinary shares; |
| · | the number of ordinary shares beneficially owned by the selling shareholders prior to the offering; |
| · | the number of outstanding ordinary shares and the number of ordinary shares underlying Secured Convertible
Guaranteed Notes due 2026 (including interest, which may be payable in ordinary shares); and |
| · | the number of ordinary shares and the percentage of ordinary shares to be beneficially owned by each selling
shareholder after the offering (assuming all of the ordinary shares are sold by such selling shareholder). |
This table was prepared solely
based on information supplied to us by Continental Stock Transfer & Trust Company, as transfer agent, the listed selling shareholders
and any Schedules 13D or 13G filed by the selling shareholders with the SEC and assumes the sale of all of the securities offered hereby.
The selling shareholders may sell all, some or none of their shares in this offering. See the disclosure under the heading “Plan
of Distribution” elsewhere in this prospectus. The selling shareholders identified in the table below may have sold, transferred
or otherwise disposed of some or all of their shares since the date of this prospectus in transactions exempt from or not subject to the
registration requirements of the Securities Act. Information concerning the selling shareholders may change from time to time and, if
necessary and required, we will amend or supplement this prospectus accordingly.
| |
| Prior to the
offering | | |
| Offered Hereby
| | |
| After the Offering | |
Shareholder | |
| Ordinary
Shares
Beneficially
Owned | | |
| Ordinary
Shares | | |
| Ordinary
Shares
Beneficially
Owned | | |
| Beneficial
Ownership
Percentage | |
El Terruño de los Cuatro S.R.L. (1) | |
| 6,325 | | |
| 6,325 | | |
| | | |
| | |
Enrique M. Baya Casal S.A. (2) | |
| 8,434 | | |
| 8,434 | | |
| | | |
| | |
Union Acquisition Associates, LLC (4) | |
| 449 | | |
| 449 | | |
| | | |
| | |
William B. Buchanan, Jr. (5) | |
| 4,910 | | |
| 4,910 | | |
| | | |
| | |
Patrick A. Sturgeon (6) | |
| 1,803 | | |
| 1,803 | | |
| | | |
| | |
Joseph LaSala (7) | |
| 721 | | |
| 721 | | |
| | | |
| | |
Michael D. Fontaine (8) | |
| 360 | | |
| 360 | | |
| | | |
| | |
Graham Powis (9) | |
| 776 | | |
| 776 | | |
| | | |
| | |
Harris Lydon (10) | |
| 4,910 | | |
| 4,910 | | |
| | | |
| | |
PENSCO Trust Company (11) | |
| 75,000 | | |
| 75,000 | | |
| | | |
| | |
Gerald W. Haddock (12) | |
| 12,500 | | |
| 12,500 | | |
| | | |
| | |
Daniel W. Fink (13) | |
| 12,500 | | |
| 12,500 | | |
| | | |
| | |
Kyle P. Bransfield (14) | |
| 8,954 | | |
| 8,954 | | |
| | | |
| | |
Ari Freisinger (16) | |
| 55,399 | | |
| 37,917 | | |
| | | |
| | |
Jasper Lake Ventures One LLC (17) | |
| | | |
| 2,896,644 | | |
| | | |
| | |
Redwood Enhanced Income Corp. (18) | |
| | | |
| 1,080,837 | | |
| | | |
| | |
Liminality Partners LP (19) | |
| | | |
| 778,203 | | |
| | | |
| | |
Notes:—
Less than
1%
| (1) | The business address of this entity is Calle 22 N° 63, Ameghino, Buenos Aires. |
| (2) | The business address of this entity is 25 de mayo 347, 5th floor, CABA. |
| (3) | Mr. Matías Kugler is alternate director of Bioceres S.A. The business address of this person
is Los Platanos 1935, Venado Tuerto, Santa Fe. |
| (4) | Represents ordinary shares held by Union Acquisition Associates, LLC, an entity controlled by Mr. Bransfield,
one of the Company’s directors. The business address of this entity is 400 Madison Ave., Suite 11A, New York, NY 10017. |
| (5) | The business address of this person is 8 Smith Ridge LN, New Canaan, CT 06840-3217. |
| (6) | The business address of this person is 34 Debrosses St., Apt 420, New York, NY 10013-0528. |
| (7) | The business address of this person is 47 Clinton St, Apt 4, New York, NY 10002-2445. |
| (8) | The business address of this person is 916 Superba Ave, Venice, CA, 90291. |
| (9) | The business address of this person is 10 Francine Dr., Greenwich, CT 06830-4703. |
| (10) | The business address of this person is 17 White St., Apt. 2B, New York, NY 10013-2485. |
| (11) | The business address of this entity is 400 Madison Avenue, RM 11A, New York, New York 10017-1948. |
| (12) | The business address of this person is 400 Madison Avenue, RM 11A, New York, New York 10017-1948. |
| (13) | The business address of this person is 400 Madison Avenue, RM 11A, New York, New York 10017-1948. |
| (14) | The business address of this person is 400 Madison Avenue, RM 11A, New York, New York 10017-1948. |
| (15) | The business address of this entity is 699 Boylston Street, 15th Floor, Boston, MA 02116. |
| (16) | The business address of this person is 3133 Sacramento Street, San Francisco, CA 94115. |
| (17) | The business address of this entity is 910 Sylvan Avenue, Suite 140, Englewood Cliffs, NJ 07632. |
| (18) | The business address of this entity is 250 W 55th St, 26th Floor, New York, NY 10019. |
| (19) | The business address of this entity is 11 Arlingon Street, Boston, MA 02116. |
Other than as described in
this prospectus or in documents incorporated by reference herein, the selling shareholders have not within the past three years had any
position, office, or other material relationship with us or any of our predecessors or affiliates other than as a holder of our securities.
None of the selling shareholders is a broker-dealer or an affiliate of a broker-dealer.
Use
of Proceeds
We will not receive any proceeds
from the sale of ordinary shares to be offered by any of the selling shareholders pursuant to this prospectus and the applicable prospectus
supplement.
Description
of Share Capital
We are a Cayman Islands
exempted company and our affairs are governed by our amended and restated memorandum and articles of association (“Articles”),
the Companies Act (As Revised) of the Cayman Islands (the “Companies Act”) and the common law of the Cayman Islands. The following
description summarizes certain terms of our shares as set out more particularly in our Articles. Because it is only a summary, it may
not contain all the information that is important to you.
Share Capital
As of the date of this
prospectus, we had (i) 100,000,000 ordinary shares ($0.0001 par value) authorized, (ii) 62,796,693 ordinary shares issued and
outstanding, (iii) 1,000,000 preference shares ($0.0001 par value) authorized, (iv) no preference shares issued and
outstanding, (v) $55.0 million principal amount of Secured Convertible Guaranteed Notes due 2026, (vi) 2,486,850 ordinary
shares reserved for our equity compensation plans. Holders of the ordinary shares are entitled to one vote for each ordinary
share.
Objects
Our Articles state that the
objects for which the Company is established are unrestricted and the Company shall have full power and authority to carry out any object
not prohibited by the laws of the Cayman Islands.
Directors
Our Articles do not restrict
a director’s power to vote in respect of any contract or transaction in which he is interested (provided that the nature of the
interest of any director in any such contract or transaction shall be disclosed by him at or prior to its consideration and any vote thereon),
vote on compensation to themselves or any other members of their body in the absence of an independent quorum or exercise borrowing powers.
There is no mandatory retirement age for our directors and our directors are not required to own securities of the Company in order to
serve as directors.
Ordinary Shares
Holders of ordinary shares
are entitled to receive ratable dividends when and if declared by our board of directors out of funds legally available therefor, subject
to any rights of any outstanding series of preference shares.
Upon our winding up, liquidation
and dissolution and after payment in full of all amounts required to be paid to creditors and to the holders of preference shares having
liquidation preferences, if any, holders of ordinary shares will be entitled to receive pro rata our remaining assets available for distribution.
The rights, powers and privileges
of holders of our ordinary shares are subject to those of holders of any shares of our preference shares or any other series or class
of shares we may authorize and issue in the future.
Our ordinary shares are not
subject to any sinking fund. All of our issued shares are fully paid up and none of our shareholders are liable for further capital calls.
There are no provisions in the Articles that discriminate against any existing or prospective holder of our ordinary shares as a result
of such shareholder owning a substantial number of shares.
Preference Shares
Our Articles authorize 1,000,000
preference shares and provide that preference shares may be issued from time to time in one or more series. Our board of directors will
be authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special
rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series. Our board of directors will
be able to, without shareholder approval, issue preference shares with voting and other rights that could adversely affect the voting
power and other rights of the holders of the ordinary shares and could have anti-takeover effects. The ability of our board of directors
to issue preference shares without shareholder approval could have the effect of delaying, deferring or preventing a change of control
of us or the removal of existing management. We have no preference shares outstanding at the date hereof. Although we do not currently
intend to issue any shares of preference shares, we cannot assure you that we will not do so in the future. No preference shares are being
issued or registered in this offering.
Voting, Appointment of Directors
Voting Power
Except as otherwise required
by law or as otherwise provided in any certificate of designation for any series of preference shares, the holders of BIOX ordinary shares
will possess all voting power for the appointment of our directors and all other matters requiring shareholder action and will at all
times vote together as one class on all matters submitted to a vote of the shareholders of BIOX. Holders of BIOX ordinary shares will
be entitled to one vote for each share held of record on all matters on which shareholders are entitled to vote generally, including the
appointment or removal of directors. Holders of BIOX ordinary shares will not have cumulative voting rights in the appointment of directors.
Preemptive or Other Rights
There will be no sinking
fund or redemption provisions applicable to BIOX shares.
Appointment of Directors
Our board currently consists
of seven directors. Each of our directors will have a term that expires at BIOX’s annual general meeting in 2023, or until their
respective successors are duly appointed and qualified, or until their earlier resignation, removal or death. There will be no cumulative
voting with respect to the appointment of directors, with the result that directors will be appointed by a majority of the votes cast
at an annual general meeting of BIOX.
General Meetings
At least five clear days’
notice are required to be given of any general meeting, which notice shall specify the place, the day and the hour of the meeting and
the general nature of the business to be conducted at the general meeting. No business will be transacted at any general meeting unless
a quorum is present. The holders of a majority of the shares being individuals present in person or by proxy or if a corporation or other
non-natural person by its duly authorized representative or proxy shall be a quorum. If a quorum is not present within half an hour from
the time appointed for the meeting to commence or if during such a meeting a quorum ceases to be present, the meeting, if convened upon
a shareholders’ request, will be dissolved and in any other case it shall stand adjourned to the same day in the next week at the
same time and/or place or to such other day, time and/or place as the directors may determine, and if at the adjourned meeting a quorum
is not present within half an hour from the time appointed for the meeting to commence, the shareholders present will be a quorum.
Annual General Meetings
Any annual general meeting
will be held at such time and place as the directors shall appoint and if no other time and place is prescribed by them, it shall be held
at the Registered Office on the second Wednesday in October of each year at ten o’clock in the morning. At these meetings the
report of the directors (if any) shall be presented. Shareholders seeking to bring business before the annual general meeting or to nominate
candidates for appointment as directors at the annual general meeting must deliver notice to the principal executive offices of the Company
not later than the close of business on the 90th day nor earlier than the close of business on the 120th day prior to the scheduled date
of the annual general meeting.
Extraordinary General Meetings
All general meetings other
than annual general meetings are extraordinary general meetings. Shareholders holding not less than 10% in par value of the issued ordinary
shares with voting rights can request, and the directors shall convene, extraordinary general meetings. Such shareholders’ request
must state the objects of the meeting and must be signed by the requesting shareholders and deposited at the Registered Office.
If there are no directors
as at the date of the deposit of the shareholders’ request or if the directors do not within twenty-one days from the date of such
request duly proceed to convene a general meeting to be held within a further twenty-one days, the requesting shareholders, or any of
them representing more than 50% of the total voting rights of all of the requesting shareholders, may themselves convene a general meeting,
but any meeting so convened shall be held no later than the day which falls three months after the expiration of the said twenty-one day
period.
Our Articles do not contain
any provisions that would have an effect of delaying, deferring or preventing a change in control of our Company. Our Articles provide
that the Company shall have the power to merge or consolidate with one or more other constituent companies (as defined in the Companies
Act) upon such terms as our directors may determine and (to the extent required by the Companies Act) with the approval of a Special Resolution.
Our Articles do not contain
any provisions governing the ownership threshold above which shareholder ownership must be disclosed.
Our Articles are not significantly
different from the requirements of the Companies Act and the conditions imposed by our Articles governing changes in capital are not more
stringent than what is required by the Companies Act.
Secured Convertible Guaranteed Notes due 2026
On August 5, 2022, we
issued US$55.0 million secured convertible guaranteed noted due 2026 (the “Secured Convertible Guaranteed Notes due 2026”)
pursuant to a note purchase agreement among us, Jasper Lake Ventures One LLC, Redwood Enhanced Income Corp, Liminality Partners LP, the
holders from time to time party thereto and Wilmington Savings Fund Society, FSB, as collateral agent. The Secured Convertible Guaranteed
Notes are secured by substantially all of the assets located in the United States of Pro Farm. In addition, the Secured Convertible Guaranteed
Notes are guaranteed by BCS Holding Inc., Bioceres Crops do Brasil Ltda., Bioceres Crops S.A., Bioceres Semillas S.A.U., Verdeca LLC,
Rasa Holding LLC, Rizobacter Argentina S.A., Rizobacter del Paraguay S.A., Rizobacter do Brasil Ltda., Rizobacter South Africa, Rizobacter
Uruguay, Rizobacter USA, LLC, Glinatur S.A., Pro Farm, Group, Inc., Pro Farm Michigan Manufacturing LLC, Pro Farm Technologies Comércio
de Insumo Agrícolas do Brasil Ltda. and Pro Farm, Inc. The Secured Convertible Guaranteed Notes mature 48 months after the
issue date, unless converted earlier, and bear interest at 5% in cash plus 4% in kind per year, payable quarterly. See “Item 4.
Information on the Company—Material Contracts—Issuance of Notes due 2026—Secured Guaranteed Notes due 2026” in
our Annual Report on Form 20-F.
Equity Compensation Plans
Bonus in Kind
It is an annual in-kind incentive
awarded in ordinary shares up to an equivalent of US$315,000, US$165,000 and US$100,000 to the Chief Executive Officer, Chief Financial
Officer and Chief Technology Officer, respectively, to tie a portion of their compensation to financial and operational objectives. Each
year the Board of Directors will define the objectives upon approval of the annual budget.
Exercise in Ordinary Shares
The number of ordinary shares
that can be awarded under each plan mentioned above is determined by using a 20-day volume weighted average price (“VWAP”)
of the Company’s ordinary shares, starting with the day on which the relevant financial and operational objectives are met by the
Company and the bonus is granted.
Vesting
50% of bonus vests immediately
on the grant date (i.e., the day immediately following the approval of the fiscal year’s financial statements by the shareholders
at the annual general meeting) if the financial and operational objectives are achieved as of such date, and the remaining 50% vests in
the subsequent 12-months, upon meeting of the financial and operational objectives.
Stock Options
Share option plan for directors
and senior management: plan granted up to 1,200,000 underlying ordinary shares. The options have an exercise price of $4.55 and expire
on October 31, 2029.
Share Option Plan for junior
management: plan granted up to 100,000 underlying ordinary shares to certain key employees. The options have an exercise price of $5.55
and expire on October 23, 2030.
Options can be exercised
for a period of up to three years, with 1/3 vesting every 12 months, and on a cashless basis at their volume weighted average price (“VWAP”)
of the ordinary shares during a twenty-day period to the date of exercise.
Employee Stock Purchase Plan (ESPP)
This is an incentive plan
for eligible employees with no stock compensation to purchase ordinary shares of the Company for up to a maximum of 15% percent of such
employee’s monthly compensation. The number of ordinary shares subject to the ESPP shall be 200,000 ordinary shares. The purchase
price will be equal to 85% of the lower of the closing price of the Company’s ordinary shares on the first business day and the
last business day of the relevant offering period.
2013 Plan
As a result of the closing
of the Pro Farm Merger, we assumed Pro Farm’s 2013 Stock Incentive Plan (the “2013 Plan”) which had been adopted by
Pro Farm’s board of directors in August 2013 and covers officers, employees, and directors of, and consultants to. Under the
2013 Plan, we may grant incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, restricted
stock units and dividend equivalent rights.
Bonus in Cash
It is an annual cash incentive
awarded up to an amount that is five times the individual’s monthly salary, which can be increased by $30,000 in value if the recipient
decides to receive the base bonus in ordinary shares, the number of which is determined based on the VWAP (as defined below), to each
of the Chief Operating Officer, Sales Director and Marketing Director and Managing Director of Rizobacter Argentina S.A. The bonus is
granted upon the meeting by the Company of certain financial and operational objectives. Each year the Board of Directors defines the
objectives upon approval of the annual budget.
Principal Differences between Cayman Islands
and U.S. Corporate Law
The Companies Act was modeled
originally after similar laws in England and Wales but does not follow subsequent statutory enactments in England and Wales. In addition,
the Companies Act differs from laws applicable to U.S. corporations and their shareholders. Set forth below is a summary of the significant
differences between the provisions of the Companies Act applicable to BIOX and the laws applicable to companies incorporated in the United
States and their shareholders.
Mergers and Similar Arrangements
The Companies Act permits
mergers and consolidations between Cayman Islands companies and between Cayman Islands companies and non-Cayman Islands companies.
For these purposes, (a) “merger”
means the merging of two or more constituent companies and the vesting of their undertaking, property and liabilities in one of such companies
as the surviving company and (b) a “consolidation” means the combination of two or more constituent companies into a
consolidated company and the vesting of the undertaking, property and liabilities of such companies in the consolidated company. In order
to effect such a merger or consolidation, the directors of each constituent company must approve a written plan of merger or consolidation,
which must then be authorized by (a) a special resolution of the shareholders of each constituent company; and (b) such other
authorization, if any, as may be specified in such constituent company’s Articles of Association. The plan must be approved by the
directors of each constituent company and filed with the Registrar of Companies together with a declaration as to: (1) the solvency
of the consolidated or surviving company, (2) the merger or consolidation is bona fide and not intended to defraud unsecured creditors
of the constituent companies; (3) no petition or other similar proceeding has been filed and remains outstanding and no order or
resolution to wind up the company in any jurisdiction, (4) no receiver, trustee, administrator or similar person has been appointed
in any jurisdiction and is acting in respect of the constituent company, its affairs or property, (5) no scheme, order, compromise
or similar arrangement has been entered into or made in any jurisdiction with creditors; (6) a list of the assets and liabilities
of each constituent company; (7) the non-surviving constituent company has retired from any fiduciary office held or will do so;
(8) that the constituent company has complied with any requirements under the regulatory laws, where relevant; and (9) an undertaking
that a copy of the certificate of merger or consolidation will be given to the members and creditors of each constituent company and published
in the Cayman Islands Gazette.
Dissenting shareholders have
the right to be paid the fair value of their shares (which, if not agreed between the parties, may be determined by the Cayman Islands’
court) if they follow the required procedures, subject to certain exceptions. Court approval is not required for a merger or consolidation
which is effected in compliance with these statutory procedures.
In addition, there are statutory
provisions that facilitate the reconstruction and amalgamation of companies, provided that the arrangement in question is approved by
a majority in number of each class of shareholders and creditors with whom the arrangement is to be made, and who must in addition represent
three-fourths in value of each such class of shareholders or creditors, as the case may be, that are present and voting either in person
or by proxy at a meeting, or meetings convened for that purpose. The convening of the meetings and subsequently the arrangement must be
sanctioned by the Grand Court of the Cayman Islands. While a dissenting shareholder would have the right to express to the court the view
that the transaction should not be approved, the court can be expected to approve the arrangement if it satisfies itself that:
| · | BIOX is not proposing to act illegally or ultra vires and the statutory provisions as to majority vote
have been complied with; |
| · | the shareholders have been fairly represented at the meeting in question; |
| · | the arrangement is such that may be reasonably approved by an intelligent and honest man of that class
acting in respect of his interest; and |
| · | the arrangement is not one that would more properly be sanctioned under some other provision of the Companies
Act or that would amount to a “fraud on the minority.” |
When a takeover offer is
made and accepted by holders of 90.0% in value of the shares affected within four months, the offeror may, within a two-month period,
require the holders of the remaining shares to transfer such shares on the terms of the offer. An objection may be made to the Grand Court
of the Cayman Islands but is unlikely to succeed unless there is evidence of fraud, bad faith or collusion.
If the arrangement and reconstruction
are thus approved, any dissenting shareholders would have no rights comparable to appraisal rights, which might otherwise ordinarily be
available to dissenting shareholders of U.S. corporations and allow such dissenting shareholders to receive payment in cash for the judicially
determined value of their shares.
Shareholders’ Suits
Class actions are not
recognized in the Cayman Islands, but groups of shareholders with identical interests may bring representative proceedings, which are
similar. However, a class action suit could nonetheless be brought in a U.S. court pursuant to an alleged violation of U.S. securities
laws and regulations.
In principle, BIOX itself
would normally be the proper plaintiff and as a general rule, whilst a derivative action may be initiated by a minority shareholder on
behalf of BIOX in a Cayman Islands court, such shareholder will not be able to continue those proceedings without the permission of a
Grand Court judge, who will only allow the action to continue if the shareholder can demonstrate that BIOX has a good case against the
defendant, and that it is proper for the shareholder to continue the action rather than the Company’s board of directors. Examples
of circumstances in which derivative actions would be permitted to continue are where:
| · | a company is acting or proposing to act illegally or beyond the scope of its authority; |
| · | the act complained of, although not beyond the scope of its authority, could be effected duly if authorized
by more than a simple majority vote that has not been obtained; and |
| · | those who control the company are perpetrating a “fraud on the minority.” |
Corporate Governance
Cayman Islands law restricts
transactions between a company and its directors unless there are provisions in the Articles of Association which provide a mechanism
to alleviate possible conflicts of interest. Additionally, Cayman Islands law imposes on directors’ duties of care and skill and
fiduciary duties to the companies which they serve. Under our Articles, a director is at liberty to vote in respect of any contract or
transaction in which he is interested, provided that the nature of the interest of any director in any such contract or transaction is
disclosed by him at or prior to its consideration and any vote thereon. The interested director shall be counted in the quorum at such
meeting and the resolution may be passed by a majority of the directors present at the meeting.
As
a result of the closing of the merger with Pro Farm, on July 12, 2022, we ceased to be a “controlled company” for purposes
of the Nasdaq rules. As a result, the Nasdaq rules require that our board of directors, compensation and nominating and governance
committees be independent. However, we have chosen to rely on Nasdaq rule 5615 in respect of our compensation and nominating and
governance committees, which provides for a phase-in period of one year to comply with such independence requirements. See
“—Item 6. Directors, Senior Management and Employees—C. Board Practices” in our Annual Report on Form 20-F.
Borrowing Powers
BIOX’s directors may
exercise all the powers of BIOX to borrow money and to mortgage or charge its undertaking, property and assets (present and future) and
uncalled capital or any part thereof and to issue debentures, debenture shares, mortgages, bonds and other such securities whether outright
or as security for any debt, liability or obligation of BIOX or of any third party. Such powers may be varied by a special resolution
under Cayman Islands law, which requires the affirmative vote of a majority of at least two-thirds of the shareholders who attend and
vote at a general meeting of the company.
Indemnification of Directors and Executive
Officers and Limitation of Liability
The Companies Act does not
limit the extent to which a company’s Articles of Association may provide for indemnification of directors and officers, except
to the extent that it may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against
civil fraud or the consequences of committing a crime. Our Articles provide that we shall indemnify and hold harmless our directors and
officers against all actions, proceedings, costs, charges, expenses, losses, damages, liabilities, judgments, fines, settlements and other
amounts incurred or sustained by such directors or officers, other than by reason of such person’s dishonesty, willful default or
fraud, in or about the conduct of our company’s business or affairs (including as a result of any mistake of judgment) or in the
execution or discharge of his duties, powers, authorities or discretions, including without prejudice to the generality of the foregoing,
any costs, expenses, losses or liabilities incurred by such director or officer in defending (whether successfully or otherwise) any civil,
criminal or other proceedings concerning BIOX or our affairs in any court whether in the Cayman Islands or elsewhere. This standard of
conduct is generally the same as permitted under the Delaware General Corporation Law for a Delaware corporation.
Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to BIOX’s directors, officers or persons controlling the Company
under the foregoing provisions, we have been informed that, in the opinion of the SEC, this indemnification is against public policy as
expressed in the Securities Act and is therefore unenforceable.
Directors’ Fiduciary Duties
Under Cayman Islands law,
directors and officers owe the following fiduciary duties:
| (i) | duty to act in good faith in what the director or officer believes to be in the best interests of the
company as a whole; |
| (ii) | duty to exercise powers for the purposes for which those powers were conferred and not for a collateral
purpose; |
| (iii) | directors should not improperly fetter the exercise of future discretion; |
| (iv) | duty to exercise powers fairly as between different sections of shareholders; |
| (v) | duty not to put themselves in a position in which there is a conflict between their duty to the company
and their personal interests; and |
| (vi) | duty to exercise independent judgment. |
In addition to the above,
directors also owe a duty of care which is not fiduciary in nature. This duty has been defined as a requirement to act as a reasonably
diligent person having both the general knowledge, skill and experience that may reasonably be expected of a person carrying out the same
functions as are carried out by that director in relation to the company and the general knowledge skill and experience of that director.
As set out above, directors
have a duty not to put themselves in a position of conflict and this includes a duty not to engage in self-dealing, or to otherwise benefit
as a result of their position. However, in some instances what would otherwise be a breach of this duty can be forgiven and/or authorized
in advance by the shareholders provided that there is full disclosure by the directors. This can be done by way of permission granted
in the memorandum and articles of association or alternatively by shareholder approval at general meetings.
A general notice may be given
to the board of directors to the effect that (1) the director is a member, director or officer of, or otherwise affiliated with,
a specified company or firm and is to be regarded as interested in any contract or arrangement which may after the date of the notice
be made with that company or firm; or (2) he or she is to be regarded as interested in any contract or arrangement which may after
the date of the notice to the board of directors be made with a specified person who is connected with him or her, will be deemed sufficient
declaration of interest. This notice shall specify the nature of the interest in question. Following the disclosure being made pursuant
to our Articles and subject to any separate requirement under applicable law or Nasdaq listing rules, and unless disqualified by the chairman
of the relevant meeting, a director may vote in respect of any transaction or arrangement in which he or she is interested and may be
counted in the quorum at the meeting.
In comparison, under Delaware
corporate law, a director of a Delaware corporation has a fiduciary duty to the corporation and its shareholders. This duty has two components:
the duty of care and the duty of loyalty. The duty of care requires that a director act in good faith, with the care that an ordinarily
prudent person would exercise under similar circumstances. Under this duty, a director must inform himself or herself of, and disclose
to shareholders, all material information reasonably available regarding a significant transaction. The duty of loyalty requires that
a director act in a manner he or she reasonably believes to be in the best interests of the corporation. He or she must not use his or
her corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates that the best interest
of the corporation and its shareholders take precedence over any interest possessed by a director, officer or controlling shareholder
and not shared by the shareholders generally. In general, actions of a director are presumed to have been made on an informed basis, in
good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may
be rebutted by evidence of a breach of one of the fiduciary duties. Should such evidence be presented concerning a transaction by a director,
a director must prove the procedural fairness of the transaction, and that the transaction was of fair value to the corporation.
Shareholder Proposals
Under the Delaware General
Corporation Law, a shareholder has the right to put any proposal before the annual general meeting, provided it complies with the notice
provisions in the governing documents. The Delaware General Corporation Law does not provide shareholders an express right to put any
proposal before the annual general meeting, but Delaware corporations generally afford shareholders an opportunity to make proposals and
nominations provided that they comply with the notice provisions in the certificate of incorporation or bylaws. A special meeting may
be called by the board of directors or any other person authorized to do so in the governing documents, but shareholders may be precluded
from calling special meetings.
The Companies Act provides
shareholders with only limited rights to requisition a general meeting, and does not provide shareholders with any right to put any proposal
before a general meeting. However, these rights may be provided in a company’s Articles of Association. Our Articles provide that
upon the requisition of one or more shareholders representing not less than one-third of the voting rights entitled to vote at general
meetings, the board will convene an extraordinary general meeting and put the resolutions so requisitioned to a vote at such meeting.
The Articles of Association provide no other right to put any proposals before annual general meetings or extraordinary general meetings.
Cumulative Voting
Under the Delaware General
Corporation Law, cumulative voting for appointments of directors is not permitted unless the corporation’s certificate of incorporation
specifically provides for it. Cumulative voting potentially facilitates the representation of minority shareholders on a board of directors
since it permits the minority shareholder to cast all the votes to which the shareholder is entitled on a single director, which increases
the shareholder’s voting power with respect to appointing such director. As permitted under Cayman Islands law, our Articles do
not provide for cumulative voting. As a result, the shareholders of BIOX are not afforded any less protections or rights on this issue
than shareholders of a Delaware corporation.
Removal of Directors
The office of a director
shall be vacated automatically if, among other things, he or she (1) becomes prohibited by law from being a director, (2) becomes
bankrupt or makes an arrangement or composition with his creditors, (3) dies or is in the opinion of all his co-directors, incapable
by reason of mental disorder of discharging his duties as director (4) resigns his office by notice to us or (5) has for more
than six months been absent without permission of the directors from meetings of the board of directors held during that period, and the
remaining directors resolve that his/her office be vacated.
Transaction with Interested Shareholders
The Delaware General Corporation
Law provides that; unless the corporation has specifically elected not to be governed by this statute, it is prohibited from engaging
in certain business combinations with an “interested shareholder” for three years following the date that this person becomes
an interested shareholder. An interested shareholder generally is a person or a group who or which owns or owned 15% or more of the target’s
outstanding voting shares or who or which is an affiliate or associate of the corporation and owned 15% or more of the corporation’s
outstanding voting shares within the past three years. This has the effect of limiting the ability of a potential acquirer to make a two-tiered
bid for the target in which all shareholders would not be treated equally. The statute does not apply if, among other things, prior to
the date on which the shareholder becomes an interested shareholder, the board of directors approves either the business combination or
the transaction which resulted in the person becoming an interested shareholder. This encourages any potential acquirer of a Delaware
corporation to negotiate the terms of any acquisition transaction with the target’s board of directors.
Cayman Islands law has no
comparable statute. As a result, BIOX cannot avail itself of the types of protections afforded by the Delaware business combination statute.
However, although Cayman Islands law does not regulate transactions between a company and its significant shareholders, it does provide
that the board of directors owe duties to ensure that these transactions are entered into bona fide in the best interests of the company
and for a proper corporate purpose and, as noted above, a transaction may be subject to challenge if it has the effect of constituting
a fraud on the minority shareholders.
Dissolution; Winding Up
Under the Delaware General
Corporation Law, unless the board of directors approves the proposal to dissolve, dissolution must be approved by shareholders holding
100% of the total voting power of the corporation. If the dissolution is initiated by the board of directors, it may be approved by a
simple majority of the corporation’s outstanding shares. Delaware law allows a Delaware corporation to include in its certificate
of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board. Under Cayman Islands law,
a company may be wound up by either an order of the courts of the Cayman Islands or by a special resolution of its members or, if the
company resolves by ordinary resolution that it be wound up because it is unable to pay its debts as they fall due. The court has authority
to order winding up in a number of specified circumstances including where it is, in the opinion of the court, just and equitable to do
so.
Under the Companies Act,
BIOX may be wound up, liquidated and dissolved by a special resolution under Cayman Islands law, which requires the affirmative vote of
a majority of at least two-thirds of the shareholders who attend and vote at a general meeting of the company. Our Articles also give
its board of directors authority to petition the Cayman Islands Court to wind up BIOX.
Variation of Rights of Shares
Under the Delaware General
Corporation Law, a corporation may vary the rights of a class of shares with the approval of a majority of the outstanding shares of that
class, unless the certificate of incorporation provides otherwise. Under our Articles, if the share capital is divided into more than
one class of shares, the rights attached to any class may only be varied with the written consent of the holders of two-thirds of the
shares of that class or the sanction of a special resolution passed at a separate meeting of the holders of the shares of that class.
Also, except with respect
to share capital (as described above), alterations to our Articles may only be made by special resolution under Cayman Islands law, which
requires the affirmative vote of a majority of at least two-thirds of the shareholders who attend and vote at a general meeting of the
company.
Amendment of Governing Documents
Under the Delaware General
Corporation Law, a corporation’s certificate of incorporation may be amended only if adopted and declared advisable by the board
of directors and approved by a majority of the outstanding shares entitled to vote, and the bylaws may be amended with the approval of
a majority of the outstanding shares entitled to vote and may, if so provided in the certificate of incorporation, also be amended by
the board of directors.
Under Cayman Islands law,
our Articles generally (and save for certain amendments to share capital described in this section) may only be amended by special resolution
under Cayman Islands law, which requires the affirmative vote of a majority of at least two-thirds of the shareholders who attend and
vote at a general meeting of the company.
Rights of Non-Resident or Foreign Shareholders
There are no limitations
imposed by our Articles on the rights of non-resident or foreign shareholders to hold or exercise voting rights on BIOX’s shares.
In addition, there are no provisions in the Articles of Association governing the ownership threshold above which shareholder ownership
must be disclosed.
Taxation
Tax considerations relating
to the ownership and disposition of any of the securities offered by this prospectus will be set forth in the applicable prospectus supplement
relating to the offering of those securities.
Plan
of Distribution
Any selling shareholders
may sell the securities offered by this prospectus:
| · | through or to underwriters; |
| · | directly to purchasers; or |
| · | through a combination of these methods. |
The prospectus supplement
relating to any offering will identify or describe:
| · | any underwriters, dealers or agents; |
| · | the purchase price of the securities; |
| · | the public offering price of the securities; |
| · | any discounts or concessions allowed or reallowed; and |
| · | confirm any exchange on which the securities will be listed, if any. |
Underwriters
If any selling shareholders
use underwriters in the sale, the selling shareholders will enter into an underwriting agreement, and a prospectus supplement will set
forth the names of the underwriters and the terms of the transaction. The underwriters will acquire securities for their own account and
may resell the securities from time to time in one or more transactions, including negotiated transactions, at a fixed public offering
price or at varying prices determined at the time of sale. Unless otherwise stated in the prospectus supplement, various conditions to
the underwriters’ obligation to purchase securities apply, and the underwriters will be obligated to purchase all of the securities
contemplated in an offering if they purchase any of such securities. Any initial public offering price and any discounts or concessions
allowed or reallowed or paid to dealers may be changed from time to time.
Any selling shareholders
may enter into derivative or other hedging transactions with third parties, or sell securities not covered by this prospectus to third
parties in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with those derivatives,
the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions.
If so, the third party may use securities covered by this prospectus including securities pledged by any selling shareholders or borrowed
from us, any selling shareholders or others to settle those sales or to close out any related open borrowing of shares, and may use securities
received from us in settlement of those derivatives to close out any related open borrowings of shares. The third party in such sale transactions
will be an underwriter and, if not identified in this prospectus, will be identified in the applicable prospectus supplement (or in a
post-effective amendment). Any selling shareholders may also sell ordinary shares short using this prospectus and deliver ordinary shares
covered by this prospectus to close out such short positions, or loan or pledge ordinary shares to financial institutions that in turn
may sell the ordinary shares using this prospectus. Any selling shareholders may pledge or grant a security interest in some or all of
the securities covered by this prospectus to support a derivative or hedging position or other obligation and, if the selling shareholders
default in the performance of its obligations, the pledgees or secured parties may offer and sell the securities from time to time pursuant
to this prospectus.
If the prospectus supplement
so indicates, any selling shareholders may authorize agents and underwriters or dealers to solicit offers by certain purchasers to purchase
the securities from the selling shareholders at the public offering price set forth in the prospectus supplement. These contracts will
be subject to only those conditions set forth in the prospectus supplement, and the prospectus supplement will set forth the commission
payable for solicitation of such offers.
Certain persons participating
in certain offerings may engage in transactions that stabilize, maintain or otherwise affect the price of the securities. Specifically,
the underwriters, if any, may over-allot in connection with the offering, and may bid for, and purchase, the securities in the open market.
Dealers
If any selling shareholders
use dealers in the sale, unless otherwise indicated in the prospectus supplement, the selling shareholders will sell securities to the
dealers as principals. The dealers may then resell the securities to the public at varying prices that the dealers may determine at the
time of resale.
Agents and Direct Sales
We or any selling shareholders
may sell securities directly or through agents that we or the selling shareholders designate. The prospectus supplement names any agent
involved in the offering and sale and states any commissions we or the selling shareholders will pay to that agent. Unless indicated otherwise
in the prospectus supplement, any agent is acting on a best efforts basis for the period of its appointment.
Institutional Investors
Unless otherwise indicated
in the prospectus supplement, any selling shareholders will authorize underwriters, dealers or agents to solicit offers from various institutional
investors to purchase securities. In this case, payment and delivery will be made on a future date that the prospectus supplement specifies.
The underwriters, dealers or agents may impose limitations on the minimum amount that the institutional investor can purchase. They may
also impose limitations on the portion of the aggregate amount of the securities that they may sell. These institutional investors include:
| · | commercial and savings banks; |
| · | educational and charitable institutions; and |
| · | other similar institutions as any selling shareholders may approve. |
The obligations of any of
these purchasers pursuant to delayed delivery and payment arrangements will not be subject to any conditions. However, one exception applies.
An institution’s purchase of the particular securities cannot at the time of delivery be prohibited under the laws of any jurisdiction
that governs:
| · | the validity of the arrangements; or |
| · | the performance by us or the institutional investor. |
Indemnification
Agreements that we or any
selling shareholders have entered into or may enter into with underwriters, dealers or agents may entitle them to indemnification by us
against certain civil liabilities. These include liabilities under the Securities Act of 1933, as amended. The agreements may also entitle
them to contribution for payments which they may be required to make as a result of these liabilities. Underwriters, dealers or agents
may be customers of, engage in transactions with, or perform services for, us in the ordinary course of business.
Cayman Data Protection Privacy Notice
We have certain duties under
the Data Protection Act (As Revised) of the Cayman Islands (the “DPA”) based on internationally accepted principles of data
privacy.
Introduction
This privacy notice puts
our shareholders on notice that through your investment in the company you will provide us with certain personal information which constitutes
personal data within the meaning of the DPA (“personal data”).
In the following discussion,
the “company” refers to us and our affiliates and/or delegates, except where the context requires otherwise.
Investor Data
We will collect, use, disclose,
retain and secure personal data to the extent reasonably required only and within the parameters that could be reasonably expected during
the normal course of business. We will only process, disclose, transfer or retain personal data to the extent legitimately required to
conduct our activities on an ongoing basis or to comply with legal and regulatory obligations to which we are subject. We will only transfer
personal data in accordance with the requirements of the DPA, and will apply appropriate technical and organizational information security
measures designed to protect against unauthorized or unlawful processing of the personal data and against the accidental loss, destruction
or damage to the personal data.
In our use of this personal
data, we will be characterized as a “data controller” for the purposes of the DPA, while our affiliates and service providers
who may receive this personal data from us in the conduct of our activities may either act as our “data processors” for the
purposes of the DPA or may process personal information for their own lawful purposes in connection with services provided to us.
We may also obtain personal
data from other public sources. Personal data includes, without limitation, the following information relating to a shareholder and/or
any individuals connected with a shareholder as an investor: name, residential address, email address, contact details, corporate contact
information, signature, nationality, place of birth, date of birth, tax identification, credit history, correspondence records, passport
number, bank account details, source of funds details and details relating to the shareholder’s investment activity.
Who this Affects
If you are a natural person,
this will affect you directly. If you are a corporate investor (including, for these purposes, legal arrangements such as trusts or exempted
limited partnerships) that provides us with personal data on individuals connected to you for any reason in relation your investment in
the Company, this will be relevant for those individuals and you should transmit the content of this Privacy Notice to such individuals
or otherwise advise them of its content.
How We May Use Your Personal Data
We, as the data controller,
may collect, store and use personal data for lawful purposes, including, in particular:
| · | where this is necessary for the performance of our rights and obligations under any purchase agreements; |
| · | where this is necessary for compliance with a legal and regulatory obligation to which we are subject
(such as compliance with anti-money laundering and FATCA/CRS requirements); and/or |
| · | where this is necessary for the purposes of our legitimate interests and such interests are not overridden
by your interests, fundamental rights or freedoms. |
Should we wish to use personal
data for other specific purposes (including, if applicable, any purpose that requires your consent), we will contact you.
Why We May Transfer Your Personal Data
In certain circumstances,
we may be legally obliged to share personal data and other information with respect to your shareholding with the relevant regulatory
authorities such as the Cayman Islands Monetary Authority or the Tax Information Authority. They, in turn, may exchange this information
with foreign authorities, including tax authorities.
We anticipate disclosing
personal data to persons who provide services to us and their respective affiliates (which may include certain entities located outside
the US, the Cayman Islands or the European Economic Area), who will process your personal data on our behalf.
The Data Protection Measures We Take
Any transfer of personal
data by us or our duly authorized affiliates and/or delegates outside of the Cayman Islands shall be in accordance with the requirements
of the DPA.
We and our duly authorized
affiliates and/or delegates shall apply appropriate technical and organizational information security measures designed to protect against
unauthorized or unlawful processing of personal data, and against accidental loss or destruction of, or damage to, personal data.
We shall notify you of any
personal data breach that is reasonably likely to result in a risk to your interests, fundamental rights or freedoms or those data subjects
to whom the relevant personal data relates.
What Rights Do Individuals Have in Respect
of Personal Data?
If you consider that your
personal data has not been handled correctly, or you are not satisfied with our responses to any requests you have made regarding the
use of your personal data, you have the right to complain to the Cayman Islands’ Ombudsman. The Ombudsman can be contacted by calling
+1 (345) 946-6283 or by email at info@ombudsman.ky.
Contacting the Company
For further information on
the collection, use, disclosure, transfer or processing of your personal data or the exercise of any of the rights listed above, please
contact us through our website at www.biocerescrops.com or +54 (341) 486-1122.
Legal
Matters
We are being represented
by Linklaters LLP with respect to certain legal matters of United States federal securities and New York State law. Certain legal matters
of United States federal securities and New York State law in connection with any offering made pursuant to this prospectus will be passed
upon for the underwriters by a law firm named in the applicable prospectus supplement. The validity of ordinary shares offered in any
offering made pursuant to this prospectus and legal matters as to Cayman Islands law has been passed upon for us by Maples and Calder
(Cayman) LLP and for any underwriters by a law firm named in the applicable prospectus supplement.
Experts
The financial statements
incorporated in this prospectus by reference to the Annual Report on Form 20-F for the year ended June 30, 2022 have been so
incorporated in reliance on the report of Price Waterhouse & Co. S.R.L., an independent registered public accounting firm, given
on the authority of said firm as experts in auditing and accounting. Further, the financial statements incorporated in this prospectus
by reference to the Pro Farm annual report on Form 10-K/A No. 2 for the year ended December 31, 2021 have been so incorporated
in reliance on the report of Marcum LLP, an independent registered public accounting firm, given on the authority of said firm as experts
in auditing and accounting.
Where
You Can Find More InforMation
We are subject to the reporting
requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are applicable to a foreign private issuer.
We file reports, including annual reports on Form 20-F, and other information with the SEC pursuant to the rules and regulations
of the SEC that apply to foreign private issuers.
Documents that we file with
the SEC are also available on the website maintained by the SEC (www.sec.gov) as well as our website in the Investor Relations section
at https://investors.biocerescrops.com/home/default.aspx. Our ordinary shares are listed on the Nasdaq under the ticker “BIOX”.
You can consult reports and other information about BIOX that it filed pursuant to the rules and regulations of the SEC.
Bioceres Crop Solutions (AMEX:BIOX)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Bioceres Crop Solutions (AMEX:BIOX)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024